Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.13 USD

4.13
1,384,226

-0.16 (-3.73%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $4.12 -0.01 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ironwood (IRWD) Reports Positive Data on Reflux Candidate

by Zacks Equity Research

Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.

    Zacks Equity Research

    Allergan Reports Positive New Data on Irritable Bowl Drug

    by Zacks Equity Research

    Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel syndrome with diarrhea (IBS-D).

      Zacks Equity Research

      Why Is Ironwood (IRWD) Up 6.9% Since the Last Earnings Report?

      by Zacks Equity Research

      Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Zacks Equity Research

        Allergan's Irritable Bowel Drug Viberzi Approved in Canada

        by Zacks Equity Research

        Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)

          Zacks Equity Research

          Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss

          by Zacks Equity Research

          Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.

            Zacks Equity Research

            Are Options Traders Betting on a Big Move in Ironwood Pharmaceuticals (IRWD) Stock?

            by Zacks Equity Research

            Huge implied volatility makes Ironwood Pharmaceuticals (IRWD) Stock lucrative to the option traders.

              Zacks Equity Research

              Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top

              by Zacks Equity Research

              Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.

                Zacks Equity Research

                Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

                by Zacks Equity Research

                Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

                  Zacks Equity Research

                  Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?

                  by Zacks Equity Research

                  Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.

                    Arpita Dutt headshot

                    5 Drug Stocks Poised to Beat Earnings Estimates in Q4

                    by Arpita Dutt

                    Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.